This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.
Berglund G, Elmståhl S, Janzon, Larsson SA . Design and feasibility. J Intern Med 1993; 233: 45–51.
Li C, Engström G, Hedblad B, Janzon L . Sex-specific cardiovascular morbidity and mortality in a cohort treated for hypertension. J Hypertens 2006; 24: 1523–1529.
Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB . Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–17.
Persson M, Carlberg B, Tavelin B, Lindholm LH . Doctors' estimation of cardiovascular risk and willingness to give drug treatment in hypertension: fair risk assessment but defensive treatment policy. J Hypertens 2004; 22: 65–71.
Cuspidi C, Michev I, Lonati L, Vaccarella A, Cristofari M, Garavelli G et al. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens 2002; 16: 699–703.
Turnbull F . Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003; 362: 1527–1535.
Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lance 2002; 359: 1004–1010.
Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP . Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. BMJ 1995; 311: 293–295.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, C., Hedblad, B., Berglund, G. et al. Hypertension in an urban population – who is treated with what and how well?. J Hum Hypertens 21, 323–326 (2007). https://doi.org/10.1038/sj.jhh.1002142
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1002142